Merck Sharp & Dohme LLC

Tempe, Arizona

OncologymRNAPhase IIIListed · MRK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)

3d agoTrial registeredJul 16, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1 registered
Jan 22, 2027
Hepatic Insufficiency · NOT_YET_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
ClinicalTrials.gov · NCT05093972 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 28, 2026
Diabetic Retinopathy, Macular Edema · NOT_YET_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
ClinicalTrials.gov · NCT07705555 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 21, 2026
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies · NOT_YET_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
ClinicalTrials.gov · NCT07709000 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 29, 2025
Healthy · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
ClinicalTrials.gov · NCT07300280 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
Dec 18, 2025
Human Immunodeficiency Virus Type 1 (HIV-1) Infection · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
ClinicalTrials.gov · NCT07266831 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 3, 2025
Healthy · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
ClinicalTrials.gov · NCT07044479 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 29, 2025
Malignant Melanoma · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
ClinicalTrials.gov · NCT06961006 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 7, 2025
Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
ClinicalTrials.gov · NCT06814132 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 2, 2025
Healthy · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
ClinicalTrials.gov · NCT06880874 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 20, 2025
Lung Neoplasm Malignant · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
ClinicalTrials.gov · NCT06788912 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Feb 26, 2025
Breast Neoplasms, Breast Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
ClinicalTrials.gov · NCT06686394 (opens the source filing in a new tab)
Trial
PHASE1 registered
Sep 24, 2024
Healthy · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
ClinicalTrials.gov · NCT06575595 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 5, 2024
Hypercholesterolemia · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
ClinicalTrials.gov · NCT06492291 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 13, 2024
Colitis, Ulcerative · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)
ClinicalTrials.gov · NCT06829225 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
May 20, 2024
Prostatic Neoplasms, Castration-Resistant · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
ClinicalTrials.gov · NCT06353386 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 1, 2024
Healthy · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
ClinicalTrials.gov · NCT06772779 (opens the source filing in a new tab)
Trial
PHASE2 registered
Dec 27, 2023
Systemic Lupus Erythematosus · TERMINATED · sponsor: Merck Sharp & Dohme LLC · Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
ClinicalTrials.gov · NCT06161116 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 8, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
ClinicalTrials.gov · NCT05947851 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jul 19, 2023
Melanoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ClinicalTrials.gov · NCT05933577 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 28, 2023
Healthy · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
ClinicalTrials.gov · NCT06816030 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 6, 2023
Healthy · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)
ClinicalTrials.gov · NCT06814106 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Dec 17, 2020
Carcinoma, Renal Cell · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
ClinicalTrials.gov · NCT04626518 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 13, 2019
Bladder Cancer · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
ClinicalTrials.gov · NCT03924856 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 21, 2018
Solid Tumors, Hematologic Malignancies · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
ClinicalTrials.gov · NCT03486873 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.92name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.92name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.92name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.91name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.91name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.91name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
new_entity links the trial record at 0.23no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
3d agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
3d agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
3d agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
3d agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
4d agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
6d agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
6d agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
7w agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
7w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
8w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
8w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
3mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
8mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
8mo agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
9mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
9mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
10mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
11mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
Jun 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
Jan 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE1 registered

PHASE3 registered

PHASE2 registered

PHASE1 registered

PHASE2/PHASE3 registered

PHASE1 registered

PHASE2 registered

PHASE1 registered

PHASE1 registered

PHASE2 registered

PHASE1/PHASE2 registered

PHASE1 registered

PHASE3 registered

PHASE1 registered

PHASE1/PHASE2 registered

PHASE1 registered

PHASE2 registered

PHASE3 registered

PHASE3 registered

PHASE1 registered

PHASE1 registered

PHASE1/PHASE2 registered

PHASE3 registered

PHASE3 registered